Patents by Inventor David J. Lockhart

David J. Lockhart has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
    Publication number: 20230364071
    Abstract: The present invention provides dosing regimens for administering pharmacological chaperones to a subject in need thereof. The dosing regimens can be used to treat disorders caused by improper protein misfolding, such as lysosomal storage disorders.
    Type: Application
    Filed: May 18, 2023
    Publication date: November 16, 2023
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, David J. Lockhart
  • Treatment of primary ciliary dyskinesia with synthetic messenger RNA
    Patent number: 11786610
    Abstract: Polynucleotides encoding peptides, proteins, enzymes, and functional fragments thereof are disclosed. The polynucleotides of the disclosure can be effectively delivered to an organ, such as the lung, and expressed within cells of the organ. The polyribonucleotides of the disclosure can be used to treat a disease or condition associated with cilia maintenance and function, impaired function of the axoneme, such as DNAI1 or DNAH5.
    Type: Grant
    Filed: October 20, 2022
    Date of Patent: October 17, 2023
    Assignee: TranscripTx, Inc.
    Inventors: David J. Lockhart, Brandon Wustman, Mirko Hennig, Daniella Ishimaru
  • TREATMENT OF PRIMARY CILIARY DYSKINESIA WITH SYNTHETIC MESSENGER RNA
    Publication number: 20230190957
    Abstract: Polynucleotides encoding peptides, proteins, enzymes, and functional fragments thereof are disclosed. The polynucleotides of the disclosure can be effectively delivered to an organ, such as the lung, and expressed within cells of the organ. The polyribonucleotides of the disclosure can be used to treat a disease or condition associated with cilia maintenance and function, impaired function of the axoneme, such as DNAI1 or DNAH5.
    Type: Application
    Filed: October 20, 2022
    Publication date: June 22, 2023
    Inventors: David J. Lockhart, Brandon Wustman, Mirko Hennig, Daniella Ishimaru
  • Treatment of primary ciliary dyskinesia with synthetic messenger RNA
    Patent number: 11642421
    Abstract: Polynucleotides encoding peptides, proteins, enzymes, and functional fragments thereof are disclosed. The polynucleotides of the disclosure can be effectively delivered to an organ, such as the lung, and expressed within cells of the organ. The polyribonucleotides of the disclosure can be used to treat a disease or condition associated with cilia maintenance and function, impaired function of the axoneme, such as DNAI1 or DNAH5.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: May 9, 2023
    Assignee: TranscripTx, Inc.
    Inventors: David J. Lockhart, Brandon Wustman, Mirko Hennig, Daniella Ishimaru
  • Treatment of primary ciliary dyskinesia with synthetic messenger RNA
    Patent number: 11510997
    Abstract: Polynucleotides encoding peptides, proteins, enzymes, and functional fragments thereof are disclosed. The polynucleotides of the disclosure can be effectively delivered to an organ, such as the lung, and expressed within cells of the organ. The polyribonucleotides of the disclosure can be used to treat a disease or condition associated with cilia maintenance and function, impaired function of the axoneme, such as DNAI1 or DNAH5.
    Type: Grant
    Filed: February 9, 2022
    Date of Patent: November 29, 2022
    Assignee: TranscripTx, Inc.
    Inventors: David J. Lockhart, Brandon Wustman, Mirko Hennig, Daniella Ishimaru
  • TREATMENT OF PRIMARY CILIARY DYSKINESIA WITH SYNTHETIC MESSENGER RNA
    Publication number: 20220211873
    Abstract: Polynucleotides encoding peptides, proteins, enzymes, and functional fragments thereof are disclosed. The polynucleotides of the disclosure can be effectively delivered to an organ, such as the lung, and expressed within cells of the organ. The polyribonucleotides of the disclosure can be used to treat a disease or condition associated with cilia maintenance and function, impaired function of the axoneme, such as DNAI1 or DNAH5.
    Type: Application
    Filed: February 9, 2022
    Publication date: July 7, 2022
    Inventors: David J. Lockhart, Brandon Wustman, Mirko Hennig, Daniella Ishimaru
  • Methods for Treatment of Fabry Disease
    Publication number: 20220160690
    Abstract: Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.
    Type: Application
    Filed: February 7, 2022
    Publication date: May 26, 2022
    Applicant: Amicus Therapeutics, Inc.
    Inventors: David J. Lockhart, Jeff Castelli
  • Methods for treatment of Fabry disease
    Patent number: 11241422
    Abstract: Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: February 8, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventors: David J. Lockhart, Jeff Castelli
  • Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
    Publication number: 20220031681
    Abstract: The present invention provides dosing regimens for administering pharmacological chaperones to a subject in need thereof. The dosing regimens can be used to treat disorders caused by improper protein misfolding, such as lysosomal storage disorders.
    Type: Application
    Filed: June 14, 2021
    Publication date: February 3, 2022
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, David J. Lockhart
  • Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
    Patent number: 11033538
    Abstract: The present invention provides dosing regimens for administering pharmacological chaperones to a subject in need thereof. The dosing regimens can be used to treat disorders caused by improper protein misfolding, such as lysosomal storage disorders.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: June 15, 2021
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, David J. Lockhart
  • TREATMENT OF PRIMARY CILIARY DYSKINESIA WITH SYNTHETIC MESSENGER RNA
    Publication number: 20210162068
    Abstract: Polynucleotides encoding peptides, proteins, enzymes, and functional fragments thereof are disclosed. The polynucleotides of the disclosure can be effectively delivered to an organ, such as the lung, and expressed within cells of the organ. The polyribonucleotides of the disclosure can be used to treat a disease or condition associated with cilia maintenance and function, impaired function of the axoneme, such as DNAI1 or DNAH5.
    Type: Application
    Filed: July 28, 2020
    Publication date: June 3, 2021
    Inventors: David J. Lockhart, Brandon Wustman, Mirko Hennig, Daniella Ishimaru
  • Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
    Patent number: 10925866
    Abstract: The present invention provides dosing regimens for administering pharmacological chaperones to a subject in need thereof. The dosing regimens can be used to treat disorders caused by improper protein misfolding, such as lysosomal storage disorders.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: February 23, 2021
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, David J. Lockhart
  • Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
    Patent number: 10525045
    Abstract: The present invention provides dosing regimens for administering pharmacological chaperones to a subject in need thereof. The dosing regimens can be used to treat disorders caused by improper protein misfolding, such as lysosomal storage disorders.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: January 7, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, David J. Lockhart
  • Methods for Treatment of Fabry Disease
    Publication number: 20190388409
    Abstract: Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.
    Type: Application
    Filed: September 9, 2019
    Publication date: December 26, 2019
    Inventors: David J. Lockhart, Jeff Castelli
  • Methods for treatment of fabry disease
    Patent number: 10406143
    Abstract: Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: September 10, 2019
    Assignee: Amicus Therapeutics, Inc.
    Inventors: David J. Lockhart, Jeff Castelli
  • Methods for treatment of Fabry disease
    Patent number: 10383864
    Abstract: Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: August 20, 2019
    Assignee: Amicus Therapeutics, Inc.
    Inventors: David J. Lockhart, Jeff Castelli
  • TREATMENT OF PRIMARY CILIARY DYSKINESIA WITH SYNTHETIC MESSENGER RNA
    Publication number: 20190117796
    Abstract: Polynucleotides encoding peptides, proteins, enzymes, and functional fragments thereof are disclosed. The polynucleotides of the disclosure can be effectively delivered to an organ, such as the lung, and expressed within cells of the organ. The polyribonucleotides of the disclosure can be used to treat a disease or condition associated with cilia maintenance and function, impaired function of the axoneme, such as DNAI1 or DNAH5.
    Type: Application
    Filed: November 15, 2018
    Publication date: April 25, 2019
    Inventors: David J. Lockhart, Brandon Wustman, Mirko Hennig, Daniella Ishimaru
  • TREATMENT OF PRIMARY CILIARY DYSKINESIA WITH SYNTHETIC MESSENGER RNA
    Publication number: 20190111074
    Abstract: Polynucleotides encoding peptides, proteins, enzymes, and functional fragments thereof are disclosed. The polynucleotides of the disclosure can be effectively delivered to an organ, such as the lung, and expressed within cells of the organ. The polyribonucleotides of the disclosure can be used to treat a disease or condition associated with cilia maintenance and function, impaired function of the axoneme, such as DNAI1 or DNAH5.
    Type: Application
    Filed: November 15, 2018
    Publication date: April 18, 2019
    Inventors: David J. Lockhart, Brandon Wustman, Mirko Hennig, Daniella Ishimaru
  • Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
    Publication number: 20180360814
    Abstract: The present invention provides dosing regimens for administering pharmacological chaperones to a subject in need thereof. The dosing regimens can be used to treat disorders caused by improper protein misfolding, such as lysosomal storage disorders.
    Type: Application
    Filed: June 18, 2018
    Publication date: December 20, 2018
    Inventors: Jeff Castelli, David J. Lockhart
  • Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
    Publication number: 20180360813
    Abstract: The present invention provides dosing regimens for administering pharmacological chaperones to a subject in need thereof. The dosing regimens can be used to treat disorders caused by improper protein misfolding, such as lysosomal storage disorders.
    Type: Application
    Filed: June 18, 2018
    Publication date: December 20, 2018
    Inventors: Jeff Castelli, David J. Lockhart